You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer
|
|---|---|
| Published in |
Journal of Translational Medicine, February 2005
|
| DOI | 10.1186/1479-5876-3-9 |
| Pubmed ID | |
| Authors |
Michael A Morse, Jennifer Garst, Takuya Osada, Shubi Khan, Amy Hobeika, Timothy M Clay, Nancy Valente, Revati Shreeniwas, Mary Ann Sutton, Alain Delcayre, Di-Hwei Hsu, Jean-Bernard Le Pecq, H Kim Lyerly |
| Abstract |
BACKGROUND: There is a continued need to develop more effective cancer immunotherapy strategies. Exosomes, cell-derived lipid vesicles that express high levels of a narrow spectrum of cell proteins represent a novel platform for delivering high levels of antigen in conjunction with costimulatory molecules. We performed this study to test the safety, feasibility and efficacy of autologous dendritic cell (DC)-derived exosomes (DEX) loaded with the MAGE tumor antigens in patients with non-small cell lung cancer (NSCLC). METHODS: This Phase I study enrolled HLA A2+ patients with pre-treated Stage IIIb (N = 4) and IV (N = 9) NSCLC with tumor expression of MAGE-A3 or A4. Patients underwent leukapheresis to generate DC from which DEX were produced and loaded with MAGE-A3, -A4, -A10, and MAGE-3DPO4 peptides. Patients received 4 doses of DEX at weekly intervals. RESULTS: Thirteen patients were enrolled and 9 completed therapy. Three formulations of DEX were evaluated; all were well tolerated with only grade 1-2 adverse events related to the use of DEX (injection site reactions (N = 8), flu like illness (N = 1), and peripheral arm pain (N = 1)). The time from the first dose of DEX until disease progression was 30 to 429+ days. Three patients had disease progression before the first DEX dose. Survival of patients after the first DEX dose was 52-665+ days. DTH reactivity against MAGE peptides was detected in 3/9 patients. Immune responses were detected in patients as follows: MAGE-specific T cell responses in 1/3, increased NK lytic activity in 2/4. CONCLUSION: Production of the DEX vaccine was feasible and DEX therapy was well tolerated in patients with advanced NSCLC. Some patients experienced long term stability of disease and activation of immune effectors. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 50% |
| Australia | 1 | 25% |
| Kenya | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Scientists | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 495 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | <1% |
| Denmark | 2 | <1% |
| Chile | 1 | <1% |
| New Zealand | 1 | <1% |
| Germany | 1 | <1% |
| Argentina | 1 | <1% |
| Portugal | 1 | <1% |
| Iran, Islamic Republic of | 1 | <1% |
| Belgium | 1 | <1% |
| Other | 0 | 0% |
| Unknown | 484 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 106 | 21% |
| Researcher | 80 | 16% |
| Student > Master | 62 | 13% |
| Student > Bachelor | 59 | 12% |
| Student > Doctoral Student | 22 | 4% |
| Other | 63 | 13% |
| Unknown | 103 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 112 | 23% |
| Agricultural and Biological Sciences | 90 | 18% |
| Medicine and Dentistry | 56 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 29 | 6% |
| Immunology and Microbiology | 23 | 5% |
| Other | 55 | 11% |
| Unknown | 130 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 28. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 March 2024.
All research outputs
#1,402,580
of 25,605,018 outputs
Outputs from Journal of Translational Medicine
#262
of 4,684 outputs
Outputs of similar age
#1,813
of 74,112 outputs
Outputs of similar age from Journal of Translational Medicine
#2
of 6 outputs
Altmetric has tracked 25,605,018 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,684 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.0. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 74,112 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.